Pharmacokinetic/pharmacodynamic analysis of high‐dose tigecycline, by Monte Carlo simulation, in plasma and sputum of patients with hospital‐acquired pneumonia

To Investigate the pharmacokinetic/pharmacodynamic (PK/PD) parameters of high‐dose tigecycline in plasma and sputum of patients with hospital‐acquired pneumonia (HAP), and provide a therapeutic regimen of multidrug‐resistant bacteria (MDRB) infections.

[1]  Aura Rusu,et al.  The Development of Third-Generation Tetracycline Antibiotics and New Perspectives , 2021, Pharmaceutics.

[2]  Yonghong Xiao,et al.  The Monte Carlo Simulation of Three Antimicrobials for Empiric Treatment of Adult Bloodstream Infections With Carbapenem-Resistant Enterobacterales in China , 2021, Frontiers in Microbiology.

[3]  A. Dokoumetzidis,et al.  Intrapulmonary Pharmacokinetics of high doses of tigecycline in patients with Ventilator-Associated Pneumonia (VAP) , 2021, International Journal of Antimicrobial Agents.

[4]  Jin Wang,et al.  Therapeutic Drug Monitoring of Tigecycline in 67 Infected Patients and a Population Pharmacokinetics/Microbiological Evaluation of A. baumannii Study , 2021, Frontiers in Microbiology.

[5]  W. Santimaleeworagun,et al.  The Synergistic Activity and Optimizing Doses of Tigecycline in Combination with Aminoglycosides against Clinical Carbapenem-Resistant Klebsiella pneumoniae Isolates , 2021, Antibiotics.

[6]  A. Isla,et al.  The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials , 2021, Pharmaceutics.

[7]  Desheng Wu,et al.  Pharmacokinetics of tigecycline in both plasma and sputum in patients with severe pneumonia. , 2021, Journal of global antimicrobial resistance.

[8]  Chengwu Shen,et al.  Dose optimization based on pharmacokinetic/pharmacodynamic target of tigecycline. , 2021, Journal of global antimicrobial resistance.

[9]  OUP accepted manuscript , 2021, Clinical Infectious Diseases.

[10]  Han Yan,et al.  Population pharmacokinetics and exposure‐response analysis of tigecycline in patients with hospital‐acquired pneumonia , 2020, British journal of clinical pharmacology.

[11]  M. Antonelli,et al.  Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections , 2020, Annals of Intensive Care.

[12]  A. van Belkum,et al.  The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase–negative staphylococci strains: a systematic review and meta-analysis , 2020, Antimicrobial Resistance & Infection Control.

[13]  B. Milošević,et al.  Hospital-acquired infections in the adult intensive care unit-Epidemiology, antimicrobial resistance patterns, and risk factors for acquisition and mortality. , 2020, American journal of infection control.

[14]  Wen-Sen Lee,et al.  Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia , 2020, Journal of clinical medicine.

[15]  I. Çelik,et al.  A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant Acinetobacter baumannii infections in intensive care units with clinical and environmental features , 2019, Annals of Clinical Microbiology and Antimicrobials.

[16]  Z. Saleem,et al.  Point prevalence surveys of health-care-associated infections: a systematic review , 2019, Pathogens and global health.

[17]  A. Musani,et al.  Community-acquired Pneumonia and Hospital-acquired Pneumonia. , 2019, The Medical clinics of North America.

[18]  Meng Chen,et al.  Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial , 2018, Antimicrobial Resistance & Infection Control.

[19]  S. Wicha,et al.  Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study , 2018, Critical Care.

[20]  C. Suetens,et al.  Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017 , 2018, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[21]  R. Lynfield,et al.  Changes in Prevalence of Health Care–Associated Infections in U.S. Hospitals , 2018, The New England journal of medicine.

[22]  A. Torres,et al.  Epidemiology of ICU-acquired pneumonia , 2018, Current opinion in critical care.

[23]  M. Yeo,et al.  Hospital-Acquired Pneumonia among Inpatients via the Emergency Department: A Propensity-Score Matched Analysis , 2018, International journal of environmental research and public health.

[24]  R. Wunderink,et al.  International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia , 2017, European Respiratory Journal.

[25]  Qingping Shi,et al.  Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation , 2017, The Annals of pharmacotherapy.

[26]  J. Xing,et al.  Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections , 2017, Antimicrobial Agents and Chemotherapy.

[27]  Peggy Cruse,et al.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  A. Amin,et al.  Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options. , 2016, Microbial drug resistance.

[29]  P. Brouqui,et al.  A new strategy to fight antimicrobial resistance: the revival of old antibiotics , 2014, Front. Microbiol..

[30]  Nikolaos A. Triarides,et al.  Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. , 2014, International journal of antimicrobial agents.

[31]  Carmen Ferrándiz-Millón,et al.  High dose of tigecycline for extremely resistant Gram-negative pneumonia: yes, we can , 2014, Critical Care.

[32]  A. Fisher,et al.  Comparison of the Bacterial Etiology of Early-Onset and Late-Onset Ventilator-Associated Pneumonia in Subjects Enrolled in 2 Large Clinical Studies , 2013, Respiratory Care.

[33]  M. Niederman,et al.  Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors , 2013, Intensive Care Medicine.

[34]  S. Troy,et al.  Tigecycline Pharmacokinetics in Subjects With Various Degrees of Renal Function , 2012, Journal of clinical pharmacology.

[35]  J. Korth-Bradley,et al.  Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with Tigecycline , 2011, Antimicrobial Agents and Chemotherapy.

[36]  T. Welte,et al.  Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. , 2009, International journal of antimicrobial agents.

[37]  M. Falagas,et al.  Old antibiotics for infections in critically ill patients , 2007, Current opinion in critical care.

[38]  J. Korth-Bradley,et al.  Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. , 2006, The Journal of antimicrobial chemotherapy.

[39]  P. Ambrose,et al.  Pharmacokinetic/pharmacodynamic profile for tigecycline—a new glycylcycline antimicrobial agent , 2005 .

[40]  J. Golden,et al.  Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. , 2005, International journal of antimicrobial agents.

[41]  S. Troy,et al.  Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects , 2005, Antimicrobial Agents and Chemotherapy.

[42]  G. Domínguez-Cherit,et al.  Prevalence of infections in intensive care units in Mexico: A multicenter study , 2000, Critical care medicine.